Spyre Therapeutics raises $400m and pivots pipeline toward hidradenitis

Spyre completed proof-of-concept for all three IBD monotherapies and launched a pivotal HS programme after a $400m equity raise.

A brightly lit sterile medical room contains two monitors displaying a circular graph, a coiled cable on a medical device, and an examination bed, all illuminated by natural light from a large window.

Spyre Therapeutics has reported a busy third quarter, completing Phase 2 proof-of-concept for all three of its inflammatory bowel disease monotherapy candidates and announcing a strategic expansion into hidradenitis suppurativa (HS) backed by a freshly closed $400 million public offering.

The Waltham-based biotech said topline induction data for SPY003, its long-acting anti-IL-23 antibody, confirmed the final of three monotherapy proof-of-concept readouts from Part A of the SKYLINE trial. All three candidates, SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003, met their primary endpoints, each delivering a statistically significant reduction in the Robarts Histopathology Index of between 9.2 and 10.7 points. Clinical remission and endoscopic improvement rates across the trio ranged from 20% to 51% across key secondary endpoints.

SKYLINE combinations and IBD outlook

Attention now shifts to SKYLINE Part B, the randomised, placebo-controlled phase assessing pairwise combinations of the three antibodies. Enrolment is running ahead of schedule, allowing Spyre to increase its target patient numbers. Topline induction data from the three combination arms, SPY120, SPY130, and SPY230, are expected in the third quarter of 2027.

The IBD combination space is becoming increasingly competitive. Established biologics targeting TNF, IL-12/23, and α4β7 individually have transformed the standard of care over the past two decades, but durable remission remains elusive for a substantial proportion of patients. Several late-stage programmes from larger companies are evaluating dual-mechanism approaches, and positive combination data from Spyre would put it in direct dialogue with those assets. Investors will want to see whether the combinations produce additive or synergistic efficacy signals that meaningfully exceed any of the monotherapies alone.

Chief executive Cameron Turtle said the company plans to deliver topline combination data "with the potential for efficacy, safety, and convenience that meaningfully surpasses today's standard of care." The Biotech Times notes this is a forward-looking claim and not yet supported by clinical data.

HS pivot and rheumatology exit

The quarter's other major strategic move was an expansion into HS. Spyre initiated the SKYLIGHT Phase 2 trial in September, pairing SPY072, its long-acting anti-TL1A antibody, with bimekizumab, a currently approved IL-17A/F inhibitor, to generate surrogate proof-of-concept for the internal SPY772 combination. Topline data are expected in late 2027 or early 2028. A pivotal monotherapy programme in HS using SPY072 is planned for 2027.

The move into HS follows external data validating TL1A inhibition in the indication, which Spyre said strengthened its conviction in the target. HS is a high-unmet-need dermatological condition affecting an estimated three million patients in the United States, with a global market the company projects could exceed $10 billion by 2035. The approved landscape remains relatively thin, making it an attractive near-term commercial opportunity for a well-funded clinical-stage player.

In contrast, Spyre confirmed it will not pursue SPY072 further in rheumatic diseases. While the RA sub-study of the SKYWAY basket trial produced statistically significant activity on at least one endpoint at both dose levels, the magnitude fell below the company's internal advancement threshold. Neither the psoriatic arthritis nor the axial spondyloarthritis sub-studies met their primary endpoints.

Financial position

Spyre reported a net loss of $96.1 million for the third quarter of 2026, up from $11.2 million in the same period a year earlier, largely reflecting higher clinical trial and manufacturing costs as R&D spending rose to $89.2 million from $45.2 million. The company exited the quarter with approximately $1.07 billion in cash and marketable securities. Pro forma for the October equity raise and at-the-market sales totalling around $396 million combined, the pro forma cash position stands at approximately $1.47 billion, extending runway into the second half of 2029.

The capital position is a meaningful differentiator in the current environment, where many clinical-stage biotechs are managing constrained runways into single key readouts. Spyre's balance sheet gives it the flexibility to run parallel programmes across IBD and HS without near-term dilution pressure.